title: [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
abstract: Seventy three patients with prostatic carcinoma (PC) and 7 patients with benign prostatic hypertrophy (BPH) in 12 institutes subcutaneously received single and multiple doses of Hoe 766, and clinical efficacy, safety and endocrine effects of drug were examined. In a single doses study, six doses were subcutaneously administered to 7 BPH and 3 with PC. Gonadotropin and testosterone levels in the blood were increased following all these doses. In a multiple study, 7 kinds of doses were given to 40 patients with PC. The optimum doses of subcutaneous injection was decided to be 500 x 3 micrograms/day based on gonadotropin and testosterone suppression. Objective response by NPCP's criteria was observed in 35.3% (complete response 5.9%, partial response 29.4%) following 3 months of Hoe 766 treatment. Adverse reactions were observed in 9 cases (12.8%): Treatment was discontinued in 3 cases (eruption in 2, nausea and vomiting in 1), and continued in 6 cases (8.6%) without any treatment required. Buserelin was thus considered to be an effective, safe drug to treat prostatic carcinoma.
authors: T
authors: T
authors: Niijima
authors: K
authors: K
authors: Isurugi
authors: K
authors: K
authors: Kawabe
authors: K
authors: K
authors: Kinoshita
authors: M
authors: M
authors: Asano
authors: K
authors: K
authors: Nakauchi
authors: K
authors: K
authors: Fujita
authors: Y
authors: Y
authors: Nishimura
authors: H
authors: H
authors: Nitoh
authors: M
authors: M
authors: Yokoyama
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011388:Prolactin / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D013972:Thyrotropin / Q000097:blood
chemical_list: D013739:Testosterone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin; D002064:Buserelin